Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF) confirmed it resumed its Phase 3 clinical program on cancer patients.
As quoted in the press release:
The SERENITY Study will use a vaporizer, a Health Canada approved Class 2 medical device as a delivery mechanism which is more acceptable to hospitals and palliative care centers. Tetra’s new drug formerly referred to as PPP-001 will be investigated in the SERENITY Study under the commercial trademark of CAUMZ. In preparation for commercialization, Tetra has decided to brand its investigational drug name for regulatory filing purposes.
In addition, the significant expansion of clinical trial sites to 20 in both Canada and the United States, will accelerate patient recruitment and help expedite Tetra’s submission to regulatory agencies.
“I am extremely pleased with Tetra’s ability to quickly resolve the problem that required us to suspend our clinical trial in advanced cancer pain. With great challenge comes great opportunity and what we are now able to deliver is a better and more reliable product,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “The continuation of our research is excellent news, not only for those suffering with advanced cancer pain and other symptoms but also for our investors. I look forward to the day when Tetra’s cannabinoid-derived drugs will help reduce, if not eliminate the reliance on drugs like Fentanyl, Oxycodone or morphine and that hopefully the study drug will be able to bring serenity to patients in their difficult journey through the disease.”